Authors
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
What Lessons Can the World Learn from Ebola?Ebola showed that when innovation is truly integrated, we can enter into unknown territories and bring new innovations with us, writes Neil Saward.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
Latest:
Europe Under Pressure: Gearing Up for a Year of Regulatory ConvergenceIn the last year regulatory authorities sharpened their focus on gathering more data and on achieving transparency and harmonization. Erick Gaussens reviews 2015 and looks at companies’ need to respond to converging demands in 2016.
Latest:
Seeing Through Physicians' Eyes: Three Priorities for PharmaPhysicians who show true empathy for their patients tend to have better outcomes. Their patients stick to treatment plans, heal faster, and have fewer hospital readmissions. The same principle applies to pharma companies trying to market to physicians, write Pratap Khedkar and Malcolm Sturgis.
Latest:
The Healing Art in MedicinePharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.
Latest:
The BUILD Checklist: A Framework for Building BrandsTaking a lead from the construction industry, Susan Abedi offers a five-step checklist for building pharma brands.
Latest:
Marketing Curative Therapies: Are We Ready?The eight trends brought on by “once-and-done” interventions that may transform thinking around healthcare marketing.
Latest:
Emergency Disaster Response: Three Ways Pharmas Can HelpAs vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.
Latest:
The Creative Impulse: Defending Pharma and Health DTCDefending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
Latest:
Access to Orphan Drugs in TurkeyGülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Latest:
Sales & Marketing: Reaching the UnreachablesThe traditional commercial sales model in biopharma of deploying teams of reps to call on physicians is broken. Here, Stephen J. Donnelly outlines a new approach.
Latest:
Navigating Success During a Rare Disease Product LaunchWebinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST
Latest:
How One Pollster Correctly Predicted BrexitOnly one polling company correctly predicted the UK's Brexit outcome. Graeme Hutton reports.
Latest:
The True Nature of Danger Behind IP Waiver ProposalIssue represents a potential threat in fighting future pandemics.
Latest:
Commercial Models for a New Healthcare EcosystemCompanies must design local commercial models that enable them to deliver value stories tailored to the specific needs of organized customers and the characteristics of local ecosystems, writes Paul Darling.
Latest:
Branding: When One is Not EnoughThe power of a second brand in the evolving global healthcare market, write Ram Subramanian and Dr. Rehan Baqri.
Latest:
Pharma dot-gov: A New Business ModelAn advocate of business system automation in the global pharma supply chain offers a six-pronged approach to adapting to the realities of a new age of mounting regulation and customer expectations.
Latest:
Eight Tips on Improving KOL EngagementGary Kaplan offers surveying tips to help identify both tactical and strategic initiatives required for a true key performance indicator.
Latest:
Supply Chain Integration or Bust… or BothThe recent formation of three mega supply-chain purchasing groups (Walgreen’s-AllianceBoots-AmerisourceBergen-Rite-Aid, McKesson-Celesio, CVS-Cardinal) denotes a shift in the balance of power between wholesalers, chains, generic pharmaceutical companies and branded pharma companies.
Latest:
Private Payers in Canada Embrace Product Listing AgreementsArvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.
